HIKSEMI Shines at Japan IT Week Autumn Show, Unveiling New Era of Intelligent Storage
TOKYO, Oct. 23, 2025 /PRNewswire/ -- Global professional storage brand HIKSEMI showcased its latest innovations at Japan IT Week Autumn 2025 under the theme "Where Data Flows, Life Evolves", highlighting full-stack storage solutions for consumer,...
Largest Milestone Payment Secured: Biokin, a Rising Chinese Pharmaceutical MNC
BEIJING, Oct. 22, 2025 /PRNewswire/ -- In October 2025, a partnership between Biokin—a rising star in China's innovative pharmaceutical sector—and global pharmaceutical leader BMS triggered a $250 million milestone payment. This is believed to be...
World's Leading Nutrition Researchers Discuss Future Lines of Research on Nuts and Dried Fruit at NUTS 2025
REUS, Spain, Oct. 22, 2025 /PRNewswire/ -- Leading health researchers from around the world have identified new priorities and directions in nut and dried fruit research, highlighting the growing body of evidence linking their consumption to...
EICMA 2025, THE 82ND EDITION IS A TRIBUTE TO PASSION
The new edition of the International Motorcycle Exhibition was presented today in Milan. With the slogan 'That's Amore', it promises to enchant its large audience once again: over 730 exhibitors, 2,000 brands, motorsport legends and an unprecedented...
The Shaw Prize Award Presentation Ceremony 2025: Continuing 22 Years of Legacy in Science and Innovation
HONG KONG, Oct. 22, 2025 /PRNewswire/ -- The Shaw Prize presented its awards to four 2025 Shaw Laureates on 21 Oct at the 2025 Award Presentation Ceremony, held in the Grand Hall of the Hong Kong Convention and Exhibition Centre. Approximately 600...
ESMO Congress 2025 Presidential Symposium Oral Presentation | Disitamab Vedotin Achieves Major Breakthrough as First-Line Treatment for Urothelial Carcinoma
BERLIN, Oct. 20, 2025 /PRNewswire/ -- At the 2025 European Society for Medical Oncology (ESMO) Congress, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing locally...
Live from ESMO | Hengrui Debuts Exhibition Booth with Landmark Data Showcasing Pharma's Emerging Innovation Power
BERLIN, Oct. 20, 2025 /PRNewswire/ -- From October 17 to 21, the European Society for Medical Oncology (ESMO) Annual Congress convened in Berlin, bringing together global leaders in oncology and pharmaceutical innovation. Representing China's...
China International College Students' Innovation Competition 2025 Finals Conclude in Zhengzhou
ZHENGZHOU, China, Oct. 20, 2025 /PRNewswire/ -- In a report published by Xinhua News Agency, the finals of the China International College Students' Innovation Competition 2025 were held in Zhengzhou from October 13 to 15. Co-organized by the...
Biparatopic HER2-targeting ADC JSKN003 Was Granted Another Breakthrough Therapy Designation for HER2-Positive Advanced Colorectal Cancer
SUZHOU, China, Oct. 20, 2025 /PRNewswire/ -- October 20, 2025- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that biparatopic HER2-targeting antibody-drug conjugate...
Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM
CHENGDU, China, Oct. 20, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, results from a Phase 3...